Mergers & Acquisitions
🇺🇸 FDA Page 6FDA news and analysis for pharmaceutical BD, investment, and market access · 4 articles on this page
Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.
Showing 61–64 of 64 articles
Biopharma M&A Strength Amidst Declining Large Deals
Despite a decline in large biopharma mergers and acquisitions, the sector remains robust. This article explores the implications for business development teams and investors.
UCB Acquires Candid Therapeutics in Major Autoimmune Drug Development Deal
UCB's acquisition of Candid Therapeutics strengthens autoimmune pipeline as Two River and Vida Ventures celebrate successful exit from clinical-stage biotech.
ARCHIMED Acquires Esperion Therapeutics in Strategic Cardiometabolic Deal
Healthcare investment firm ARCHIMED announces definitive agreement to acquire Esperion Therapeutics, maker of cholesterol drugs NEXLETOL and NEXLIZET.
Teva Acquires Emalex Biosciences for $700M to Gain First-in-Class Tourette Syndrome Drug Ecopipam
Teva's $700M acquisition of Emalex adds NDA-ready ecopipam, a first-in-class dopamine D1 antagonist for pediatric Tourette syndrome with FDA Fast Track status.